FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

The U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). This marks the first approved treatment for TED with labeling that includes data for both active and chronic TED, based on positive results from two pivotal Phase 3 clinical trials. Lumvoa is administered as five intravenous infusions over 12 weeks and demonstrated rapid onset of clinical benefit.